<DOC>
	<DOCNO>NCT01679834</DOCNO>
	<brief_summary>This multicenter , observational study ass efficacy safety Pegasys ( peginterferon alfa 2a ) dual- triple therapy patient chronic hepatitis C. Patients receive Pegasys and/or ribavirin and/or protease inhibitor accord local guideline . Data collect 96 week .</brief_summary>
	<brief_title>An Observational Study Pegasys Dual- Triple-Therapy Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Diagnosis chronic hepatitis C Patients receive treatment Pegasys and/or Copegus ( ribavirin ) and/or protease inhibitor accord local label Contraindications Pegasys Copegus Not willing unable sign write informed consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>